WEST PHARMACEUTICAL SERVICES, INC. Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized of -$4.00 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-04-25.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized · last filed 2024-04-25
- WEST PHARMACEUTICAL SERVICES, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2024-03-31 was -$4.00M, a 137.38% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2023-03-31 was $10.70M, a 137.78% increase year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2022-03-31 was $4.50M, a 62.50% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2021-03-31 was $12.00M.
- WEST PHARMACEUTICAL SERVICES, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2023 was -$14.30M, a 307.25% decline from fiscal 2022.
- WEST PHARMACEUTICAL SERVICES, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2022 was $6.90M, a 64.29% increase from fiscal 2021.
- WEST PHARMACEUTICAL SERVICES, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2021 was $4.20M.
- WEST PHARMACEUTICAL SERVICES, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2020 was -$22.20M.
| Period end | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 3 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 6 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 9 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$4.00M 10-Q · filed 2024-04-25 | |||
| 2023-12-31 | -$14.30M 10-K · filed 2024-02-20 | |||
| 2023-09-30 | $18.20M 10-Q · filed 2023-10-26 | |||
| 2023-06-30 | $11.50M 10-Q · filed 2023-07-27 | |||
| 2023-03-31 | $10.70M 10-Q · filed 2023-04-27 | |||
| 2022-12-31 | $6.90M 10-K · filed 2023-02-21 | |||
| 2022-09-30 | $9.30M 10-Q · filed 2022-10-27 | |||
| 2022-06-30 | -$4.60M 10-Q · filed 2022-07-28 | |||
| 2022-03-31 | $4.50M 10-Q · filed 2022-04-28 | |||
| 2021-12-31 | $4.20M 10-K · filed 2022-02-22 | |||
| 2021-09-30 | $19.00M 10-Q · filed 2021-10-28 | |||
| 2021-06-30 | $17.10M 10-Q · filed 2021-07-30 | |||
| 2021-03-31 | $12.00M 10-Q · filed 2021-04-30 | |||
| 2020-12-31 | -$22.20M 10-K · filed 2021-02-23 | |||
| 2020-09-30 | -$21.80M 10-Q · filed 2020-10-23 | |||
| 2020-06-30 | -$5.50M 10-Q · filed 2020-07-24 | |||
| 2020-03-31 | -$6.90M 10-Q · filed 2020-04-24 | |||
| 2019-12-31 | -$1.50M 10-K · filed 2020-02-24 | |||
| 2019-09-30 | $2.50M 10-Q · filed 2019-10-29 | |||
| 2019-06-30 | $500.00K 10-Q · filed 2019-07-29 | |||
| 2019-03-31 | -$3.10M 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $200.00K 10-K · filed 2019-02-28 | |||
| 2018-09-30 | $3.60M 10-Q · filed 2018-10-30 | |||
| 2018-06-30 | $9.40M 10-Q · filed 2018-07-31 | |||
| 2018-03-31 | $11.50M 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |